Search company, investor...

454 Life Sciences

454.com

Founded Year

2000

Stage

Acquired | Acquired

Total Raised

$52.5M

Valuation

$0000 

About 454 Life Sciences

454 Life Sciences develops and commercializes novel instrumentation for high-throughput DNA sequencing. Specific applications include whole-genome sequencing, RNA analysis and ultra-deep sequencing of target genes. The hallmarks of 454 Sequencing are its simple, unbiased sample preparation and massively parallel sequencing, which makes large-scale scientific projects feasible and more affordable. In 2005, 454 Sequencing and the Genome Sequencer 20 System won The Wall Street Journal's top Innovation Award for 2005, and received an R&D 100 Editor's Choice Award as one of the most technologically significant products in 2006.

Headquarters Location

20 Commercial Street

Branford, Connecticut, 06405,

United States

203-871-2300

Missing: 454 Life Sciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: 454 Life Sciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing 454 Life Sciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

454 Life Sciences is included in 1 Expert Collection, including Omics.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

454 Life Sciences Patents

454 Life Sciences has filed 31 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • DNA
  • Genetics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/16/2019

4/20/2021

Molecular biology, Biotechnology, DNA, Genetics, Molecular biology techniques

Grant

Application Date

1/16/2019

Grant Date

4/20/2021

Title

Related Topics

Molecular biology, Biotechnology, DNA, Genetics, Molecular biology techniques

Status

Grant

Latest 454 Life Sciences News

Global Next-Generation Sequencing (NGS) Market Worth USD 10,371.1 Million by 2021 - Analysis, Technologies & Forecasts Report 2016-2021 - Key Vendors: 454 Life Sciences, Agilent Technologies, Illumina - Research and Markets

Mar 14, 2016

Global Next-Generation Sequencing (NGS) Market Worth USD 10,371.1 Million by 2021 - Analysis, Technologies & Forecasts Report 2016-2021 - Key Vendors: 454 Life Sciences, Agilent Technologies, Illumina - Research and Markets March 14, 2016 10:25 AM Eastern Daylight Time DUBLIN--( BUSINESS WIRE )--Research and Markets ( http://www.researchandmarkets.com/research/6c73qm/nextgeneration ) has announced the addition of the "Next-Generation Sequencing (NGS) Market by Platforms (HiSeq, MiSeq, HiSeq X Ten/X Five, Nextseq500, Ion Proton, PGM, IonS5, PacBio & Sequel), Services (Targeted Sequencing, De novo),Application (Diagnostic, Drug Discovery) - Global Forecasts to 2021" report to their offering. The next generation sequencing market is expected to reach USD 10,371.1 Million by 2021 from USD 4,031.7 Million in 2016, at a CAGR of 20.8% between 2016 and 2021. The drivers for the NGS market include technological advancements in NGS products, increasing applications of NGS, entry of new market players, and increasing partnerships & collaborations among market players plus growing incidences of cancer, inherited rare disorders, and pre- and neo-natal disorders. This report segments the global NGS market into products & services, technology, application, and end user. The NGS market, by products & services is segmented into pre-sequencing products & services, NGS platforms, consumables, sequencing services, data analysis/bioinformatics. The pre-sequencing products & services segment if further categorized into DNA fragmentation. End repair, A-tailing, & size selection; library preparation & target enrichment; and quality control. Companies Mentioned: 454 Life Sciences Corporation (Roche Holding AG) Agilent Technologies, Inc.

454 Life Sciences Frequently Asked Questions (FAQ)

  • When was 454 Life Sciences founded?

    454 Life Sciences was founded in 2000.

  • Where is 454 Life Sciences's headquarters?

    454 Life Sciences's headquarters is located at 20 Commercial Street, Branford.

  • What is 454 Life Sciences's latest funding round?

    454 Life Sciences's latest funding round is Acquired.

  • How much did 454 Life Sciences raise?

    454 Life Sciences raised a total of $52.5M.

  • Who are the investors of 454 Life Sciences?

    Investors of 454 Life Sciences include Roche Holding, TowerBrook Capital Partners, Cooper Hill Partners and CuraGen.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.